GSK : Q1 2024 results infographic

GSK makes a strong start to 2024 with improving

Total sales

£7.4bn

+10%, +13%

including and excluding COVID-19 solutions

Vaccines

£2.3bn

+16%, +22%

including and excluding COVID-19 solutions

Specialty Medicines

£2.5bn

+17%, +19%

including and excluding COVID-19 solutions, with HIV +14%

outlook for the year

General Medicines

£2.6bn

+1%

"We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic areas this quarter: infectious diseases, HIV, respiratory/immunology and oncology. We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024."

Core operating profit

£2.4bn

+27%, +35% including and excluding COVID-19 solutions

Dividend

15p

Total EPS		Core EPS
25.7p -19%		[43.1p]
		+28%, +37% including and
		excluding COVID-19 solutions
72	4
vaccines and		positive data read
medicines in pipeline		outs on phase III
		medicines

Emma Walmsley

Chief Executive Officer, GSK

Journalists/media see press release on www.gsk.com for full details on Q1 2024.

Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on page 49 of the press release.

Product group sales may not add to total sales due to rounding. References to growth are at constant exchange rates (CER) ).

Ahead Together